Cardiovascular thromboembolic events associated with febuxostat: Investigation of cases from the FDA adverse event reporting system database

Conclusion: AERS indicated potential signals of febuxostat-associated cardiovascular thromboembolic events. AERS is not capable of establishing the causal link and detecting the true frequency of an adverse event associated with a drug. The positive IC value found in this study merits continued surveillance and assessment of cardiovascular thromboembolic events associated with Febuxostat.
Source: Seminars in Arthritis and Rheumatism - Category: Rheumatology Authors: Source Type: research